Market Overview:
The global tularemia infection drug market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of tularemia infections, rising demand for effective and safe drugs for the treatment of tularemia infections, and growing investments by pharmaceutical companies in research and development (R&D) activities for the development of new drugs for treating tularemia infections. However, factors such as high cost of treatment and lack of awareness about tularemia infections are likely to restrain the growth of this market during the forecast period. On the basis of type, streptomycin is expected to account for a major share in terms revenue generated by this market during 2018-2030. This can be attributed to its high efficacy against various strainsof Francisella Tularensis bacteria that cause Tularemia infection.
Product Definition:
Tularemia is a rare bacterial infection caused by the bacterium Francisella tularensis. The most common way to get tularemia is by breathing in tiny droplets of water or soil that contain the bacteria. You can also get it from eating or drinking food or water that has been contaminated with the bacteria, and from contact with infected animals, such as rabbits, deer, and prairie dogs. Tularemia Infection Drug is important because it can be used to prevent and treat tularemia infections.
Streptomycin:
Streptomycin is an antibiotic drug, which is produced by fermentation of Streptomyces griseus. It works by killing bacteria that causes infections in the upper respiratory tract, urinary bladder, and female reproductive system. The drug was first approved in 1943 for the treatment of sore throat and tonsillitis; it was later on used as a front line treatment for tuberculosis (TB), but its application shifted to bacterial pneumonia after TB was successfully treated with antibiotics.
Gentamicin:
Gentamicin is an antibiotic used to treat bacterial infections. It works by killing the bacteria or slowing down their growth rate. The drug has a wide range of applications including skin, soft tissue, and ocular infections; pneumonia; and urinary tract infection.
Application Insights:
Based on the application, the market is segmented into hospitals and clinics, drugstores and pharmacies, others. Hospitals and clinics were estimated to be the largest revenue generating centers in 2017. This can be attributed to factors such as high prevalence of infection among patients with animal bites or scratches at hospitals & clinics that are engaged in wound treatment or surgeries.
Drugstores and pharmacies are anticipated to witness lucrative growth over the forecast period owing to increasing awareness about preventive measures taken against diseases by using vaccines. Tularemia vaccine is available for purchase directly from manufacturers online without a prescription; however, it remains expensive compared with other vaccines costing around USD 25-50 per dose depending upon brand name/quality of vaccine purchased (i.e., Pfizer).
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, advanced healthcare infrastructure and high awareness levels coupled with the availability of effective treatment for tularemia are some factors responsible for its dominance. Moreover, increasing incidence of zoonotic diseases such as leptospirosis and hantavirus is also expected to drive the regional market over the forecast period.
Asia Pacific is expected to witness lucrative growth during the forecast period owing to rising prevalence of neglected tropical diseases (NTDs) in countries such as India and China that results in increased mortality rate along with a rise in hospital admissions. In addition, growing investment by leading pharmaceutical companies for developing novel drugs targeting unmet medical needs will further propel this region’s growth over next eight years.
Growth Factors:
- Increasing incidence of tularemia infection across the globe.
- Growing awareness about tularemia infection and its treatment options among people.
- Rising demand for effective and safe drugs for the treatment of tularemia infection.
- Technological advancements in drug development process that are expected to offer better therapeutic options for tularemia infection patients in the near future.
Scope Of The Report
Report Attributes
Report Details
Report Title
Tularemia Infection Drug Market Research Report
By Type
Streptomycin, Gentamicin, Doxycycline, Ciprofloxacin, Others
By Application
Hospitals and Clinics, Drugstore, Others
By Companies
Pfizer, Zydus Cadila, Sun Pharmaceutical, GlaxoSmithKline, Alkem, Bayer AG, Lupin Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
214
Number of Tables & Figures
150
Customization Available
Yes, the report can be customized as per your need.
Global Tularemia Infection Drug Market Report Segments:
The global Tularemia Infection Drug market is segmented on the basis of:
Types
Streptomycin, Gentamicin, Doxycycline, Ciprofloxacin, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals and Clinics, Drugstore, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Zydus Cadila
- Sun Pharmaceutical
- GlaxoSmithKline
- Alkem
- Bayer AG
- Lupin Pharmaceuticals
Highlights of The Tularemia Infection Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Streptomycin
- Gentamicin
- Doxycycline
- Ciprofloxacin
- Others
- By Application:
- Hospitals and Clinics
- Drugstore
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Tularemia Infection Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Tularemia is a bacterial infection that can be contracted through contact with infected animals or their secretions, such as saliva or blood. The most common form of the disease is tularemia pneumonia, which can be fatal if not treated quickly. Treatment typically involves antibiotics and supportive care.
Some of the major players in the tularemia infection drug market are Pfizer, Zydus Cadila, Sun Pharmaceutical, GlaxoSmithKline, Alkem, Bayer AG, Lupin Pharmaceuticals.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Tularemia Infection Drug Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Tularemia Infection Drug Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Tularemia Infection Drug Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Tularemia Infection Drug Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Tularemia Infection Drug Market Size & Forecast, 2020-2028
4.5.1 Tularemia Infection Drug Market Size and Y-o-Y Growth
4.5.2 Tularemia Infection Drug Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Streptomycin
5.2.2 Gentamicin
5.2.3 Doxycycline
5.2.4 Ciprofloxacin
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospitals and Clinics
6.2.2 Drugstore
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Tularemia Infection Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Tularemia Infection Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Streptomycin
9.6.2 Gentamicin
9.6.3 Doxycycline
9.6.4 Ciprofloxacin
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospitals and Clinics
9.10.2 Drugstore
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Streptomycin
10.6.2 Gentamicin
10.6.3 Doxycycline
10.6.4 Ciprofloxacin
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospitals and Clinics
10.10.2 Drugstore
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Streptomycin
11.6.2 Gentamicin
11.6.3 Doxycycline
11.6.4 Ciprofloxacin
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospitals and Clinics
11.10.2 Drugstore
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Streptomycin
12.6.2 Gentamicin
12.6.3 Doxycycline
12.6.4 Ciprofloxacin
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospitals and Clinics
12.10.2 Drugstore
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Streptomycin
13.6.2 Gentamicin
13.6.3 Doxycycline
13.6.4 Ciprofloxacin
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospitals and Clinics
13.10.2 Drugstore
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Tularemia Infection Drug Market: Competitive Dashboard
14.2 Global Tularemia Infection Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 Zydus Cadila
14.3.3 Sun Pharmaceutical
14.3.4 GlaxoSmithKline
14.3.5 Alkem
14.3.6 Bayer AG
14.3.7 Lupin Pharmaceuticals
